Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma.
We have genetically engineered a cell line, and developed a reproducible process, for the expression and purification of biologically active recombinant human thyroid stimulating hormone (rhTSH).rhTSH was expressed by co-transfecting a human alpha-subunit cDNA with a human beta-subunit partial genomic clone into Chinese Hamster Ovary (CHO) cells. Stable transfectants which expressed high levels of rhTSH were selected, and subsequently cultured on microcarrier beads. The rhTSH-containing media, produced under serum-free conditions, was clarified and purified by a combination of ion exchange, dye and gel filtration chromatographies. Individual step recoveries were greater than 90% with the exception of a very conservative pooling of the final gel filtration step (78% recovery) that resulted in a cumulative yield of 54% for the purification process. Purity of the final bulk material was judged to be > 99% by SDS polyacrylamide gel electrophoresis (SDS-PAGE), reverse phase HPLC, and size exclusion chromatography. Initial characterization of the oligosaccharide composition indicated the presence of partially sialylated bi- and triantenary complex oligosaccharides. Purified rhTSH was active in a thyroid membrane bioactivity assay with a specific activity of 8.2 IU/mg. The in vivo activity of rhTSH in cynomolgus monkeys appeared to be equal to or greater than that reported for bovine TSH (bTSH) in human subjects. The rapid clearance phase half-life of rhTSH was approximately 35 minutes while the post-distribution phase half life was approximately 9.8 hours. Furthermore, the monkeys showed cumulative increases in minimum plasma rhTSH levels when given three daily intramuscular (IM) rhTSH injections; a phenomenon not observed when bTSH had been administered to humans. The rhTSH showed no evidence of toxic or adverse effects when administered at doses up to 7.2 IU/kg and 0.52 IU/kg in rat and monkey, respectively. These are 50X and 4X multiples of the bTSH doses of 0.143 IU/kg (10 IU/70kg) previously administered to humans.
Cole
E S
ES
Therapeutic Protein Development Department, Genzyme Corporation, Framingham, MA 01701-9322.
Lee
K
K
Lauziere
K
K
Kelton
C
C
Chappel
S
S
Weintraub
B
B
Ferrara
D
D
Peterson
P
P
Bernasconi
R
R
Edmunds
T
T
D000595:Amino Acid Sequence; D000818:Animals; D001709:Biotechnology; D016466:CHO Cells; D002845:Chromatography; D002851:Chromatography, High Pressure Liquid; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009362:Neoplasm Metastasis / Q000175:diagnosis*; D051381:Rats; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000493:pharmacokinetics; D013964:Thyroid Neoplasms; D013972:Thyrotropin / Q000096:biosynthesis* / Q000737:chemistry / Q000493:pharmacokinetics
D011994:Recombinant Proteins; D013972:Thyrotropin; D000242:Cyclic AMP